GSK (GSK LN) Q4 (GBP): Revenue 8.62bln (exp. 8.42bln), Adj. EPS 0.255 (exp. 0.224), affirms FY26 guidance and 2031 sales outlook
Importance
Level 1
- Vaccine sales 2.29bln (exp. 2.20bln)
- Shingrix revenue 1.01bln (exp. 827mln)
FY26 guidance:
- Expect 2026 turnover growth of between 3-5%; Core operating profit growth of between 7-9%; Core EPS growth of between 7-9%
#UNITED KINGDOM#EUROPE#GLAXOSMITHKLINE PLC#GSK.LN#IMPORTANT#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FTSE 100 INDEX#GSK PLC#GSK#FTSE 100